Yantai Dongcheng Pharmaceuticl Gp Co Ltd

Chart & Performance

D1W1MN

P/E

66.75

P/S

4.28

EPS

0.22

Div Yield, %

0.84%

Shrs. gr., 5y

0.55%

Rev. gr., 5y

-0.84%

Revenues

2.87b

-12.42%

Net income

184m

-12.35%

CFO

287m

+3.69%

Dividend

Jun 24, 20240.125 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API, chemical medicines, proprietary Chinese medicines, and nuclide drugs products in China. It offers heparin, chondroitin sulphate, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C for use in the therapeutic areas of cardiovascular, oncology, urology, orthopedics, and other therapeutic areas. The company also exports its products to approximately 40 countries and regions, including the Europe, America, Asia Pacific, and internationally. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is based in Yantai, China.

URL

http://www.dcb-group.com

IPO date

May 25, 2012

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT